So, if you’re like most, these new medicines are new to you. And you can look them up online, you can figure out how to deal with them by asking friends and neighbors. But, really, until you’ve tried it, until you’ve used it, it doesn’t really click.
In an interview with OncLive, Dr. John Marshall discusses second-line treatment options for patients with mCRC, along with who is most appropriate to receive regorafenib and how to manage doses and toxicities when using the multikinase inhibitor.
“When I went to medical school, I was taught that colon cancer is a 50 and older disease, but on any given day more than half of my clinic is filled with patients under the age of 50,” said Dr. John Marshall
John L. Marshall, MD; Mohamed E. Salem, MD; and Monica Chacha, RN, highlight the standard of care in the first and second lines of therapy for colorectal cancer, and the factors to consider when deciding on treatment options for patients in the refractory setting.
John L. Marshall, MD; Mohamed E. Salem, MD; and Monica Chacha, RN, provide insight on the use of regorafenib in advanced colorectal cancer, including their clinical experience and the importance of early side effect management.